-
Of Chloroquine and COVID-19: Evidence and Limits
2026-08-14
Touret and de Lamballerie’s commentary places early chloroquine enthusiasm for COVID-19 within decades of antiviral research, showing why cell-culture activity cannot substitute for animal or clinical evidence. Its cross-model analysis highlights inconsistent efficacy, possible disease aggravation, and the need for carefully controlled translational studies.
-
IR-1061: From NIR-II Signal to Translational Strategy
2026-08-14
IR-1061 is more than a near infrared fluorescent dye: its optical behavior can be reshaped by formulation, molecular packing, and tumor-membrane interactions. This thought-leadership guide connects mechanistic evidence with practical workflow design for researchers developing fluorescent dye for in vivo imaging, optical imaging, and translational biomedical applications.
-
(S)-(+)-Dimethindene maleate: Protocol Guide
2026-08-13
This guide helps researchers use (S)-(+)-Dimethindene maleate as a controlled pharmacological probe when studying M2 muscarinic and H1 histamine receptor activity. It is suitable for in vitro receptor, pathway, autonomic regulation, cardiovascular, and respiratory research, but it should not be treated as a clinically validated reagent or used for diagnostic or medical purposes.
-
Cy5-UTP RNA Probes for SPEN-XIST Assays
2026-08-13
Cy5-UTP enables direct, far-red visualization of RNA synthesized by T7 RNA polymerase, connecting precise RNA probe synthesis with SPEN-XIST binding studies, FISH, and multiplexed array workflows. This guide translates structural findings from XIST A-repeat research into practical labeling, assay-design, and troubleshooting decisions.
-
AZD1390: ATM Kinase Inhibitor Workflow
2026-08-12
AZD1390 provides a precise way to suppress ATM signaling while testing radiation response, replication stress, and G-quadruplex tolerance. This workflow connects glioma and lung cancer models with the emerging REV1–DHX36 mechanism, helping researchers separate DNA damage signaling from downstream repair and cell-fate effects.
-
LY-411575: A Causal Notch Assay Tool
2026-08-12
LY-411575 is a potent gamma-secretase inhibitor for dissecting amyloid precursor protein and Notch biology. This article presents a mechanism-first framework for connecting molecular cleavage assays with tumor immune microenvironment decisions in Alzheimer’s disease research and cancer research.
-
Hesperadin: Aurora B Kinase Inhibitor Guide
2026-08-11
Hesperadin is an ATP-competitive Aurora B kinase inhibitor used to interrogate mitosis, chromosome segregation, and cytokinesis. Reported biochemical and cellular benchmarks support its use as a mechanistic research tool, but they do not establish clinical efficacy or direct inhibition of mitotic checkpoint complex disassembly.
-
Notch Inhibition Sensitizes TNBC to Checkpoint Blockade
2026-08-11
Shen et al. show that blocking Notch-driven cytokine programs can remodel the tumor immune microenvironment of triple-negative breast cancer and improve the response to sequential immune checkpoint blockade. The study links reduced tumor-associated macrophage recruitment with stronger cytotoxic T-cell activity and marked suppression of lung metastases, providing a mechanistic framework for combination immunotherapy.
-
DIDS: Chloride Channel Inhibition and Research Uses
2026-08-10
DIDS, also called 4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid, is a research anion transport inhibitor with activity against selected chloride channels and related transport systems. Product data support its use in chloride-current, vascular, TRPV1, hyperthermia, and neonatal ischemia-hypoxia models, but its assay-dependent selectivity limits direct clinical interpretation.
-
Amikacin Sulfate: Research Workflows and Optimization
2026-08-09
Build more reproducible MAC, S. aureus, and intracellular infection assays with Amikacin Sulfate, from fresh-solution preparation through CFU and host-cell readouts. The workflow also shows how delivery concepts from antimicrobial-peptide research can inform, but not replace, direct aminoglycoside validation.
-
ASB3 E3 Ligase Targets MAVS in Antiviral Immunity
2026-08-08
A 2024 Cell Death & Differentiation study identifies ASB3 as an E3 ubiquitin ligase that suppresses antiviral innate immunity by promoting K48-linked ubiquitination and proteasomal degradation of MAVS. The work connects ASB3-dependent loss of MAVS to reduced TBK1–IRF3 signaling and increased susceptibility to influenza infection, providing a mechanistic framework for studying host regulation of RIG-I-like receptor pathways.
-
Sulfo-Cy5 NHS Ester for Aqueous Labeling
2026-08-07
Sulfo-Cy5 NHS ester, also called Sulfo-Cyanine5 Succinimidyl Ester, is an amine-reactive fluorescent probe for biomolecule labeling in aqueous workflows. Its sulfonated design supports water-compatible protein conjugation, while the supplier reports near-infrared optical performance and successful LLP2A labeling for cellular imaging of VLA-4.
-
Annexin V-FITC/PI Apoptosis Assay Kit: Practical Guidance
2026-08-07
The Annexin V-FITC/PI Apoptosis Assay Kit enables rapid, reproducible detection and quantification of apoptotic and necrotic cells, critical for cell death pathway analysis. It is optimized for research settings requiring clear discrimination of early and late apoptosis by flow cytometry or fluorescence microscopy, but is not suitable for clinical diagnostics or medical decision-making.
-
Metal-Ion-Chelating l-Phe Nanostructures Enhance Tumor Immun
2026-08-06
This study introduces metal-ion-chelating l-phenylalanine nanostructures as a novel approach to reprogram the tumor microenvironment and sensitize breast tumors to immune checkpoint blockade. By modulating dendritic cell electrophysiology and leveraging short-term starvation, this work advances mechanistic understanding of overcoming immunosuppressive barriers in cancer immunotherapy.
-
Hierarchical ROS-Responsive Platform Mitigates Diabetic Peri
2026-08-06
This study introduces a hierarchically targeted, ROS-responsive nanoparticle hydrogel platform for treating diabetic periodontitis by repairing mitochondrial dysfunction in M1 macrophages. The approach interrupts the ROS-driven inflammatory cycle, significantly reducing periodontal tissue destruction and enhancing bone regeneration, suggesting a promising direction for managing chronic inflammation in diabetes-associated periodontal disease.